Contract Services

NanoCrystal^® Technology – problem dissolved^™

NanoCrystal^® technology now commercialized involves reducing the size of drug particles, typically to less than 2,000 nanometers. By reducing particle size, the drug’s exposed surface area is increased. The nanoparticles are then stabilized to maintain their reduced particle size. The result is a stable drug formulation that exhibits an increased dissolution rate.

Alkermes Contract Pharma Services’ NanoCrystal technology is a drug enablement and optimization technology applicable to poorly water-soluble compounds and is part of a suite of technologies that Alkermes Contract Pharma Services offers to partners. 

NanoCrystal Technology Facts: 

• Five products launched using NanoCrystal technology
• Over 1,200 patents/patent applications in U.S. and rest of the world
• Optimized and simplified from almost 20 years of development behind the technology
• Applicable to all dosage forms
• Manufactured at commercial scale since 2001. 

To find out if your drug candidate would benefit from our expertise in bioavailability enhancement please contact us.

Back to Technologies

NanOsmotic^® Technology

Alkermes Contract Pharma Services’ NanOsmotic^® technology combines the expertise built up around our Oral Controlled Release technologies with the NanoCrystal^® technology to provide a technology with a number of potential performance advantages over alternative technologies in the poorly water-soluble drug delivery space.

This enhancement of the NanoCrystal technology has the ability to maintain a drug in its original crystalline form until biologically activated. Following activation, a thermodynamically enhanced form of the drug is delivered and maintained for a period of time sufficient to achieve absorption.

Benefits of the NanOsmotic Technology

The major benefits the NanOsmotic technology may offer over competing technologies in the poorly water-soluble drug delivery space include:

• Rate and extent of drug release that is substantially independent of pH
• Rapid dissolution of drug within the formulation
• Potential for delivery of drug to GI tract in higher energy state
• Excellent chemical and/or physical stability
• High drug loading
• Ability to achieve programmable drug release
• Improved bioavailability, rate of absorption and dose linearity.

Features of the technology: The combined delivery system can be presented as a tablet/capsule. The final dosage form can display the characteristics of a number of different conventional dosage forms – immediate release, delayed release or modified release. A number of drug candidates are currently in development using this combination technology approach.

To find out if your drug candidate would benefit from our expertise in bioavailability enhancement please contact us.

Back to Technologies